title: Lung cancer screening: the way forward.
abstract: To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.
authors.affiliation: Department of Surgery and Oncology, Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, Liverpool L3 9TA, UK. J.K.Field@liv.ac.uk
authors.forename: J K
authors.initials: JK
authors.lastname: Field
authors.forename: S W
authors.initials: SW
authors.lastname: Duffy
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D008400:Mass Chest X-Ray; D009313:National Health Programs; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D006113:United Kingdom